STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTLA
  4. [144] Intellia Therapeutics, Inc. SEC Filing

John M. Leonard to sell 22,675 Intellia (NASDAQ: NTLA) shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (symbol NTLA) received a notice that John M. Leonard intends to sell common stock under Rule 144. The planned sale covers 22,675 shares of common stock through UBS Financial Services Inc., with an aggregate market value of $293,641.25, listed on NASDAQ and noted with a proposed sale date of 08/20/2026.

The shares relate to earlier acquisitions from stock option exercises by the issuer, including 3,000 shares on 04/13/2021 and 19,675 shares on 02/09/2021, both for cash. UBS Financial Services Inc. signed as attorney-in-fact for John Leonard.

Positive

  • None.

Negative

  • None.
Shares to be sold 22,675 shares of common stock Planned Rule 144 sale for John M. Leonard
Aggregate market value $293,641.25 Value of 22,675 NTLA shares proposed for sale
Proposed sale date 08/20/2026 Date associated with the planned Rule 144 sale
Shares from 04/13/2021 option exercise 3,000 shares Common stock acquired via stock option exercise for cash
Shares from 02/09/2021 option exercise 19,675 shares Common stock acquired via stock option exercise for cash
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 04/13/2021 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as attorney-in-fact for John Leonard"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for NTLA disclose?
It discloses that John M. Leonard intends to sell 22,675 shares of Intellia Therapeutics, Inc. common stock under Rule 144, through UBS Financial Services Inc., with an aggregate market value of $293,641.25 and a noted proposed sale date of 08/20/2026.

How many NTLA shares are planned to be sold under this Form 144?
The notice states that 22,675 shares of Intellia Therapeutics, Inc. common stock are planned to be sold. The filing lists these shares with an aggregate market value of $293,641.25 and identifies UBS Financial Services Inc. as the broker for the transaction.

What is the approximate market value of the NTLA shares in this Form 144?
The filing reports an aggregate market value of $293,641.25 for the 22,675 shares of Intellia Therapeutics, Inc. common stock proposed to be sold under Rule 144, with the sale to be executed through UBS Financial Services Inc.

When are the NTLA shares in this Form 144 expected to be sold?
The notice indicates a proposed sale date of 08/20/2026 for the 22,675 shares of Intellia Therapeutics, Inc. common stock to be sold under Rule 144 through UBS Financial Services Inc.

How were the NTLA shares in the Form 144 originally acquired?
The filing shows the shares were acquired via stock option exercises from the issuer: 3,000 shares on 04/13/2021 and 19,675 shares on 02/09/2021, both for cash consideration.

Who is executing the planned sale of NTLA shares in the Form 144?
The broker identified is UBS Financial Services Inc., and the Form 144 is signed “/s/ UBS Financial Services Inc, as attorney-in-fact for John Leonard,” indicating UBS is acting under a power of attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR